Zhang N, Wu J, Wang Q, Liang Y, Li X, Chen G, Zhou F, et al. Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer J. 2023;13(1):82.

Article  PubMed  PubMed Central  Google Scholar 

Pulte D, Jansen L, Brenner H. Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century. Blood Cancer J. 2020;10(5):56.

Article  PubMed  PubMed Central  Google Scholar 

Carter JL, Hege K, Yang J, Kalpage HA, Su Y, Edwards H, Ge Y, et al. Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. Signal Transduct Target Ther. 2020;5(1):288.

Article  PubMed  PubMed Central  Google Scholar 

Rosenquist R, Bernard E, Erkers T, Scott DW, Itzykson R, Rousselot P, Smedby KE, et al. Novel precision medicine approaches and treatment strategies in hematological malignancies. J Intern Med. 2023;294(4):413–36.

Article  CAS  PubMed  Google Scholar 

Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020;17(8):474–502.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, Valent P, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022;43(4):280–99.

Article  PubMed  PubMed Central  Google Scholar 

Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Reviews Cardiol. 2020;17(8):474–502.

Article  CAS  Google Scholar 

Wu F, Yang J, Liu J, Wang Y, Mu J, Zeng Q, Zhou H, et al. Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer. Signal Transduct Target Ther. 2021;6(1):218.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, Yang S, et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther. 2021;6(1):201.

Article  PubMed  PubMed Central  Google Scholar 

Arora G, Adinugraha P, Aijaz A, Vargas Pelaez A, Rachko M. Pericardial Effusion Secondary to Nilotinib in an Elderly Patient With Chronic Myelogenous Leukemia. Cureus. 2022;14(4):e23855.

PubMed  PubMed Central  Google Scholar 

Zhang L, Meng L, Liu B, Zhang Y, Zhu H, Cui J, Wang J, et al. Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study. Clin Cancer Res. 2021;27(1):70–7.

Article  PubMed  Google Scholar 

Takakuwa T, Otomaru I, Araki T, Miura A, Fujitani Y, Mochizuki Y, Yamamura R, et al. The First Autopsy Case of Fatal Acute Cardiac Failure after Administration of Carfilzomib in a Patient with Multiple Myeloma. Case Rep Hematol. 2019;2019:1816287.

PubMed  PubMed Central  Google Scholar 

Bockorny M, Chakravarty S, Schulman P, Bockorny B, Bona R. Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature. Acta Haematol. 2012;128(4):244–7.

Article  PubMed  Google Scholar 

Verbesselt M, Meekers E, Vandenberghe P, Delforge M, Vandenbriele C. Combined lenalidomide/bortezomib for multiple myeloma complicated by fulminant myocarditis: a rare case report of widely used chemotherapy. Eur Heart J Case Rep. 2022;6(3):ytac093.

Article  PubMed  PubMed Central  Google Scholar 

Alali Y, Baljevic M. Bortezomib-Induced Perimyocarditis in a Multiple Myeloma Patient: A Case Report. Case Rep Oncol. 2021;14(3):1853–9.

Article  PubMed  PubMed Central  Google Scholar 

Tam CS, Opat S, D’Sa S, Jurczak W, Lee H-P, Cull G, et al. Dimopoulos M. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood. 2020;136(18):2038–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brown JR, Eichhorst B, Hillmen P, Jurczak W, Kaźmierczak M, Lamanna N, et al. Shadman M. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med. 2023;388(4):319–32.

Article  CAS  PubMed  Google Scholar 

Jouni H, Aubry MC, Lacy MQ, Vincent Rajkumar S, Kumar SK, Frye RL, Herrmann J. Ixazomib cardiotoxicity: A possible class effect of proteasome inhibitors. Am J Hematol. 2017;92(2):220–1.

Article  CAS  PubMed  Google Scholar 

Newman M, Malla M, Gojo I. Azacitidine-Induced Pericarditis: A Case Series. Pharmacotherapy. 2016;36(4):443–8.

Article  CAS  PubMed  Google Scholar 

Ismayl M, Kc A, Thandra A, Sricharoen N, Arouni A. Azacitidine-induced myopericarditis in acute myeloid leukemia. Proc (Bayl Univ Med Cent). 2022;35(6):849–51.

PubMed  PubMed Central  Google Scholar 

Fogaça da Mata M, Vieira Martins M, Rato J, Madeira M, Gonçalves J-P, Teixeira A, Anjos R. Azacitidine-induced massive pericardial effusion in a child with myelodysplastic syndrome. J Oncol Pharm Pract. 2022;28(4):975–8.

Article  PubMed  Google Scholar 

Sheel A, Bae J, Asada A, Otterson GA, Baliga RR, Koenig KL. Reversible cardiomyopathy in a patient with chronic myelomonocytic leukemia treated with decitabine/cedazuridine: a case report. Cardiooncology. 2023;9(1):4.

PubMed  Google Scholar 

Johnson IM, Karrar O, Rana M, Iftikhar M, Chen S, McCullough K, et al. Gangat N. Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents. Br J Haematol. 2024;204(4):1232–7.

Article  CAS  PubMed  Google Scholar 

Amitai I, Gafter-Gvili A, Shargian-Alon L, Raanani P, Gurion R. Obinutuzumab-related adverse events: A systematic review and meta-analysis. Hematol Oncol. 2021;39(2):215–21.

Article  CAS  PubMed  Google Scholar 

Xiang S, Shen R, Xiang J, Zhu N, Gu J, Shen J, Ge H, et al. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for Bruton’s tyrosine kinase inhibitors (BTKis) single and its combination therapy. Expert Opin Drug Saf. 2024;23(5):627–36.

Article  CAS  PubMed  Google Scholar 

Passalia C, Minetto P, Arboscello E, Balleari E, Bellodi A, Del Corso L, et al. Ghio R. Cardiovascular adverse events complicating the administration of rituximab: report of two cases. Tumori. 2013;99(6):e288–92.

Article  Google Scholar 

Cheungpasitporn W, Kopecky SL, Specks U, Bharucha K, Fervenza FC. Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy. J Ren Inj Prev. 2017;6(1):18–25.

Article  CAS  PubMed  Google Scholar 

Armitage JD, Montero C, Benner A, Armitage JO, Bociek G. Acute coronary syndromes complicating the first infusion of rituximab. Clin Lymphoma Myeloma. 2008;8(4):253–5.

Article  PubMed  Google Scholar 

Keswani AN, Williams C, Fuloria J, Polin NM, Jahangir E. Rituximab-Induced Acute ST Elevation Myocardial Infarction. Ochsner J. 2015;15(2):187–90.

PubMed  PubMed Central  Google Scholar 

Matsuo K, Ishiguro T, Najama T, Shimizu Y, Kobayashi Y, Mutou M. Nivolumab-induced Myocarditis Successfully Treated with Corticosteroid Therapy: A Case Report and Review of the Literature. Intern Med. 2019;58(16):2367–72.

Article  PubMed  PubMed Central  Google Scholar 

Fukushima S, Okamoto E, Uchida T, Kijima T. A Case of Nivolumab-Induced Multiorgan Toxicity: Concurrent Myocarditis and Interstitial Pneumonia. Cureus. 2025;17(3):e80732.

PubMed  PubMed Central  Google Scholar 

Monge C, Maeng H, Brofferio A, Apolo AB, Sathya B, Arai AE, et al. Bilusic M. Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report. J Immunother Cancer. 2018;6(1):150.

Article  PubMed  PubMed Central